OncoCyte Corporation (OCX)
Company Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally.
The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.
It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies.
The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system.
OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
| Country | United States |
| IPO Date | Dec 30, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 43 |
| CEO | Joshua Riggs |
Contact Details
Address: 15 Cushing Irvine, California United States | |
| Website | https://oncocyte.com |
Stock Details
| Ticker Symbol | OCX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001642380 |
| CUSIP Number | 68235C107 |
| ISIN Number | US68235C2061 |
| Employer ID | 27-1041563 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael D. West Ph.D. | Scientific Advisor, Co-Chief Executive Officer of Biotime,Inc. & President of Biotime,Inc. |
| Joshua Riggs | President, Chief Executive Officer & Director |
| Andrea Susan James | Chief Financial Officer |
| Yuh-Min Chiang Ph.D. | Chief Technology Officer |
| Dr. Ekkehard Schutz M.D., Ph.D. | Chief Science Officer |
| Dr. Paul R. Billings FACP, M.D. | Consulting Chief Medical Officer |
| James Liu | Senior Director, Controller & Principal Accounting Officer |
| Peter Hong | Vice President, General Counsel & Secretary |
| Sandra O'Donald | Senior Vice President of Business Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 24, 2025 | D | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 11, 2025 | 4 | Filing |
| Feb 11, 2025 | 4 | Filing |
| Feb 10, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Feb 10, 2025 | 4 | Filing |
| Feb 10, 2025 | 8-K | Current Report |
| Feb 10, 2025 | 424B5 | Filing |
| Feb 04, 2025 | 4 | Filing |
| Jan 31, 2025 | 4 | Filing |